home

conference

esc-2020

ESC Congress 2020

Slideshows

Dr. Gregory Weiss compiles thoughts and perspective on hot line trials presented at ESC Congress 2020.

ESC Congress 2020 Hot Line Reviews

Patrick Campbell is the senior editor of Practical Cardiology, as well as its sister publication Endocrinology Network. Prior to joining these brands, he led coverage of cardiology and diabetes with HCPLive. Before joining parent company MJH Life Sciences in 2019, he spent time as a beat reporter with the Pocono Record in Stroudsburg, PA and Star News Group in Manasquan, NJ. He also touts experience in multimedia, having spent time as a freelance multimedia specialist with NJ Advance Media and multimedia coordinator at the Pocono Record. In his free time, he enjoys traveling, sports, and exploring the great outdoors. Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Videos

Lead investigator of the PARALLAX trial discusses whether he feels clinical data related to sacubitril/valsartan is strong enough to warrant prescribing it for HFpEF patients.

Burkert Pieske, MD: Sacubitril/Valsartan for HFpEF

Deepak Bhatt, MD, of Brigham and Women's Hospital, offers perspective on REDUCE-IT analyses and icosapent ethyl (Vascepa) data presented at ESC Congress 2020.

Deepak Bhatt, MD: Icosapent Ethyl and REDUCE-IT Data from ESC Congress 2020

Milton Packer, MD, discusses how EMPEROR-Reduced data influences the way clinicians view the SGLT2 inhibitor class and its uses. 

Milton Packer, MD: The Evolution of the SGLT2 Inhibitor Class

Podcasts

A podcast featuring an interview with Prof. Kausik Ray centered around the latest inclisiran data presented at ESC Congress 2020. 

Prof. Kausik Ray: Inclisiran Data at ESC Congress 2020

Articles

A study from ESC Congress 2020 details the effects of initiating rhythm control within the first year of an atrial fibrillation diagnosis. 

Early Rhythm Control Cuts Event Rate in Afib Patients

Lead investigator of IMPACT-AFib discusses the results of the study and how they inform clinicians on strategies to improve oral anticoagulant use. 

Sean Pokorney, MD: IMPACT-AFib and the Struggle to Improve Anticoagulant Adherence

Investigators found no benefit from the discontinuation of ACE inhibitors/ARBs in patients hospitalized with COVID-19 in a prospective, randomized, phase 4 trial. 

BRACE CORONA: No Benefit from Discontinuing ACEs/ARBs in Patients with COVID-19

The largest and most comprehensive look at blood pressure therapies and cardiovascular disease risk to date is providing an overview of the effects of antihypertensive therapy at varying levels of baseline blood pressure.

Blood Pressure Therapies Lower CVD Risk, Regardless of Disease History

Results of HOME-PE suggest an approach using HESTIA was noninferior to sPESI for patients with acute pulmonary embolism. 